drugset

drugset / Trial / NCT03945721

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

NCT03945721 ↗

Phase 1 Active not recruiting 21 enrolled Massachusetts General Hospital Tesaro, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This research study involves Niraparib as a possible treatment for triple negative breast cancer.

Timeline

Start: 2019-07-11
Primary completion: 2026-12-31
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Niraparib	Small molecule	—	Oral

Indications